Payment overview · 2025
General Payments
$743.52
16 reported records · 7 companies
Healthcare provider profile · identity verified
Julio Alberto Ramirez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BRONX, NY · NPI 1962494948
Verified facts
What the public records show
CMS Open Payments records show Julio Alberto Ramirez, MD received $743.52 in general payments during 2025 across 16 reported records.
Xeris Pharmaceuticals, Inc. accounted for 36.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 459 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $272.91 | 36.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $149.10 | 20.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $133.85 | 18.0% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $95.06 | 12.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.33 | 5.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.80 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.47 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $743.52 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $272.91 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $149.10 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $133.85 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $95.06 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $75.60 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.33 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.80 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.80 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 98 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 214 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
459 | 84 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
98 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
167 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
214 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
115 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1116 | 307 |
| Amlodipine Besylate | Amlodipine Besylate | 690 | 181 |
| Omeprazole | Omeprazole | 488 | 135 |
| Jardiance | Empagliflozin | 459 | 84 |
| Metformin Hcl | Metformin Hcl | 296 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 283 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 279 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 278 | 88 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 262 | 69 |
| Diclofenac Sodium | Diclofenac Sodium | 254 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 253 | 69 |
| Lisinopril | Lisinopril | 252 | 59 |
| Chlorthalidone | Chlorthalidone | 249 | 63 |
| Losartan Potassium | Losartan Potassium | 230 | 63 |
| Farxiga | Dapagliflozin Propanediol | 219 | 39 |
| Ozempic | Semaglutide | 214 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 195 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 52 |
| Metformin Hcl Er | Metformin Hcl | 182 | 53 |
| Gabapentin | Gabapentin | 181 | 55 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 180 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 178 | 55 |
| Trulicity | Dulaglutide | 167 | 30 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 165 | 49 |
| Simvastatin | Simvastatin | 159 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 155 | 36 |
| Meclizine Hcl | Meclizine Hcl | 151 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 149 | 37 |
| Montelukast Sodium | Montelukast Sodium | 148 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 143 | 23 |
| Alendronate Sodium | Alendronate Sodium | 142 | 28 |
| Glimepiride | Glimepiride | 125 | 34 |
| Eliquis | Apixaban | 115 | 26 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 113 | 23 |
| Linzess | Linaclotide | 110 | 25 |
| Ammonium Lactate | Ammonium Lactate | 109 | 32 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 106 | 33 |
| Famotidine | Famotidine | 104 | 33 |
| Synjardy | Empagliflozin/Metformin Hcl | 102 | 19 |
| Mounjaro | Tirzepatide | 98 | 19 |
| Sertraline Hcl | Sertraline Hcl | 94 | 26 |
| Nifedipine Er | Nifedipine | 92 | 27 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 91 | 21 |
| Meloxicam | Meloxicam | 91 | 39 |
| Januvia | Sitagliptin Phosphate | 84 | 19 |
| Celecoxib | Celecoxib | 82 | 45 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 82 | 16 |
| Doxepin Hcl | Doxepin Hcl | 80 | 32 |
| Furosemide | Furosemide | 75 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 23 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 74 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 36 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 74 | 20 |
| Ibuprofen | Ibuprofen | 70 | 34 |
| Mometasone Furoate | Mometasone Furoate | 66 | 35 |
| Atenolol | Atenolol | 64 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 13 |
| Carvedilol | Carvedilol | 60 | 19 |
| Novolog Flexpen | Insulin Aspart | 59 | suppressed |
| Finasteride | Finasteride | 57 | 19 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 57 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 50 | 14 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 50 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 48 | 12 |
| Labetalol Hcl | Labetalol Hcl | 47 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 47 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Glipizide Er | Glipizide | 46 | suppressed |
| Prednisone | Prednisone | 46 | 26 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 45 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Ezetimibe | Ezetimibe | 42 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Glipizide | Glipizide | 39 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 38 | 32 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 36 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 12 |
| Vascepa | Icosapent Ethyl | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 19 |
| Folic Acid | Folic Acid | 33 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Naproxen | Naproxen | 33 | 17 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 32 | 11 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 28 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | 12 |
| Dexilant | Dexlansoprazole | 26 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | 11 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Nabumetone | Nabumetone | 20 | 11 |
| Ramipril | Ramipril | 20 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | 12 |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Eplerenone | Eplerenone | 16 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | 12 |
| Mupirocin | Mupirocin | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acetazolamide Er | Acetazolamide | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Glipizide Xl | Glipizide | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $743.52 · 16 records | Xeris Pharmaceuticals, Inc. | ABRYSVO, COMIRNATY, Cologuard Collection Kit, MOUNJARO, Ozempic, PREVNAR 20, RECORLEV, REPATHA, Rybelsus, VOQUEZNA, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error